Episode Details
Back to Episodes
News Explained: Why did the Indian Patent Office reject J&J’s application to extend its patent on an anti-TB drug?
Published 3 years, 7 months ago
Description
The Indian Patents Office on Thursday rejected an application of global pharma major Johnson and Johnson seeking an extension of its patent on anti-Tuberculosis (TB) drug Bedaquiline beyond July 2023, when it is set to expire. Why is this significant? Will it help TB patients in India? The Hindu businessline's Senior Deputy Editor G Naga Sridhar explains in this episode of News Explained. Tune in to know more.
--- Send in a voice message: https://podcasters.spotify.com/pod/show/business-line/message